CME OUTFITTERS

THE FORCE AWAKENS

Unlocking the Potential of IL-23–Targeted Therapies in the Treatment of IBD

Sunday, May 4, 2025
6:30–8:00 PM PT

Doors open: 6:00 PM PT
Manchester Grand Hyatt San Diego
Grand Hall D

THE FORCE AWAKENS

Unlocking the Potential of IL-23–Targeted Therapies in the Treatment of IBD

Activity Description

The therapeutic armamentarium for inflammatory bowel disease (IBD) is expanding with the advent of anti–IL-23 therapies. The unique clinical profiles of new and emerging agents make it necessary that treatment decisions are guided by evolving knowledge of the science surrounding cytokine-targeting therapies. With an established efficacy in treating both bio-naïve and bio-experienced patients, and the increased flexibility in administration routes (intravenous vs subcutaneous), the growing class of distinctive IL-23–targeting agents amplifies the importance of clinicians utilizing the most current research and guidelines when determining with patients where to best position IL-23 agents in the treatment of their IBD.

In this CME Outfitters live symposium, faculty will examine the role of pro-inflammatory cytokines in the pathogenesis of IBD, discern differences in IL-23 binding among IL-23p19–targeted therapies, assess the safety and efficacy of IL-23p19–targeted therapies for the treatment of IBD, and explore when to incorporate IL-23p19–targeted therapies into the management of patients with IBD.

Target Audience

Gastroenterologists, gastroenterology fellows/trainees, physician associates (PAs), nurse practitioners (NPs), and nurses

Financial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, both are Johnson and Johnson companies.

Faculty

Miguel Regueiro
MD (Moderator)

Marita Kametas
MSN, APN, FNP-BC, CMSRN, COCN

Edward V. Loftus, Jr.
MD

Millie D. Long
MD, MPH

Learning Objectives

At the conclusion of this activity, learners will be able to better:

- Assess the role of pro-inflammatory cytokines such as IL-23 in the pathogenesis of IBD
- Differentiate IL-23 binding among the IL-23p19–targeted therapies
- Evaluate the safety and efficacy of IL-23p19–targeted therapies available for the treatment of IBD
- Incorporate IL-23p19–targeted therapies into the multidisciplinary management of appropriate patients with IBD

© 2025 CME OUTFITTERS. ALL RIGHTS RESERVED.

THE FORCE AWAKENS

Unlocking the Potential of IL-23–Targeted Therapies in the Treatment of IBD

Accreditation

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME)

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC)

This activity is designated for 1.5 contact hours.

California Residents: Provider approved by the California Board of Registered Nursing, Provider # CEP 15510, for 1.5 Contact Hours.

PAs (AAPA)

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

RCP Canada

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

MIPS

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Certificate of Participation

This activity was certified for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*™.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

© 2025 CME OUTFITTERS. ALL RIGHTS RESERVED.

THE FORCE AWAKENS

Unlocking the Potential of IL-23–Targeted Therapies in the Treatment of IBD



Miguel Regueiro

MD (Moderator)

Chief, Digestive Disease Institute
Professor in the Department of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, Ohio

Miguel Regueiro, MD, is the chair of the Digestive Disease and Surgery Institute at Cleveland Clinic in Ohio, as well as a professor in the Department of Medicine of Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. His main clinical and research interest is inflammatory bowel diseases (IBD) with a focus on the natural course of Crohn's disease and ulcerative colitis. He leads research on postoperative prevention of Crohn's disease as well as on developing new models of health care, including the first-of-its kind specialty medical home for IBD.



Marita Kametas

MSN, APN, FNP-BC, CMSRN, COCN

Inflammatory Bowel Disease Advanced Practice Nurse
Manager of Gastroenterology Advanced Practice Provider Services
The University of Chicago Medicine
Chicago, Illinois

Marita Kametas, MSN, APN, FNP-BC, CMSRN, COCN, is a family nurse practitioner and ostomy specialist who treats adult patients with inflammatory bowel disease (IBD). She serves as the manager for the Advanced Practice Gastroenterology Service at the University of Chicago in Illinois. She volunteers her time as a mentor for the Crohn's and Colitis Advanced Practice Provider (APP) mentorship program and delivers empowering lectures to APPs to optimize their care of patients with IBD. She was awarded the honor of Distinguished APP of 2023 at the University of Chicago. She currently is pursuing a doctorate in nursing practice and a master's degree in public health at Johns Hopkins University in Baltimore, Maryland, with an emphasis on diversity, equity, and inclusion.

© 2025 CME OUTFITTERS. ALL RIGHTS RESERVED.

THE FORCE AWAKENS

Unlocking the Potential of IL-23–Targeted Therapies in the Treatment of IBD



Edward V. Loftus, Jr.

MD

Maxine and Jack Zarrow Family Professor
of Gastroenterology Specifically in IBD
Division of Gastroenterology and Hepatology
Mayo Clinic College of Medicine and Science
Co-Director, Advanced Inflammatory Bowel Disease Fellowship
Mayo Graduate School of Medicine
Rochester, Minnesota

Edward V. Loftus, Jr., MD, is a gastroenterologist with extensive experience as a lecturer and clinician researcher in the field of inflammatory bowel diseases. He is the Maxine and Jack Zarrow Family Professor of Gastroenterology Specifically for IBD at Mayo Clinic College of Medicine and Science in Rochester, Minnesota. Dr. Loftus has published more than 475 original articles, book chapters, and editorials, and over 700 abstracts. He was awarded the American Gastroenterologist Association's Distinguished Clinician Award and the Research Mentor Award in Immunology, Microbiology, and Inflammatory Bowel Diseases (IMIBD) in 2019. Dr. Loftus has been the principal investigator on several funded studies focusing on the epidemiology and natural history of inflammatory bowel disease and has served as the local PI on multiple clinical trials of investigational agents for IBD. He currently serves on the steering committees of several clinical development programs in IBD.



Millie D. Long

MD, MPH

Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
Department of Medicine
University of North Carolina
Chapel Hill, North Carolina

Millie D. Long, MD, MPH, is board certified in internal medicine, preventive medicine, and gastroenterology. She received her medical degree from University of Virginia in 2002. She then completed residency in internal medicine and a chief residency at University of Alabama–Birmingham. She completed fellowships in gastroenterology and hepatology, preventive medicine, and inflammatory bowel disease, all at University of North Carolina. She is currently a professor of medicine in the Department of Medicine and director of the Gastroenterology and Hepatology Fellowship Program at University of North Carolina–Chapel Hill.

Dr. Long's clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) Center. Her research interests include prevention of complications of IBD, women's health, and clinical epidemiology. Dr. Long has contributed to more than 200 peer-reviewed publications, book chapters, and review articles, and to the medical literature. She is the current co-editor in chief of the *American Journal of Gastroenterology*. She also serves as an invited reviewer for journals such as *Inflammatory Bowel Diseases* and *Gastroenterology*.

Dr. Long is a fellow of the American College of Gastroenterology, where she serves on the board of trustees. She is also a fellow of the American Gastroenterological Association and the Crohn's and Colitis Foundation, where she co-chairs the Clinical Research Alliance.

© 2025 CME OUTFITTERS. ALL RIGHTS RESERVED.

THE FORCE AWAKENS

Unlocking the Potential of IL-23–Targeted Therapies in the Treatment of IBD

Disclosures and Declarations

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty

Dr. Regueiro reports the following financial relationships:

Consultant: AbbVie Inc; Amgen Inc.; Boehringer Ingelheim; Bristol Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; Prometheus Biosciences, Inc.; Salix Pharmaceuticals; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Ms. Kametas reports the following financial relationships:

Advisory Board: Lilly and Pfizer Inc.

Consultant: TKG Therapeutics, Inc.

Grants: GI Research Foundation

Speakers Bureau: AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Pfizer Inc.

Dr. Loftus reports the following financial relationships:

Advisory Board: Lilly and Morphic Therapeutic, Inc.

Consultant: AbbVie Inc.; Alvotech; Amgen Inc.; Arena Pharmaceuticals, Inc.; Astellas Pharma Inc.; Avalo Therapeutics, Inc.; Boehringer Ingelheim; Bristol Myers Squibb Company; Celltrion, Inc.; Fresenius Kabi; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Gossamer Bio; Iterative Health; Janssen Pharmaceuticals, Inc.; Ono Pharma USA, Inc.; Protagonist Therapeutics Inc.; Sun. Pharma; Surrozen; Takeda Pharmaceuticals U.S.A.; TR1X Bio; and UCB, Inc.

Grants: AbbVie Inc.; AstraZeneca; Bristol Myers Squibb Company; Celgene Corporation/Receptos, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A.; Theravance Biopharma; and UCB, Inc.

Stock Shareholder (directly purchased): Exact Sciences Corporation

Dr. Long reports the following financial relationships:

Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; Prometheus Biosciences, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Target RWE

Research Support: Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Peer Reviewers

Rebecca Vargas-Jackson, MD–no disclosures to report.

Albert Eubanks, Jr., RN–no disclosures to report.

CMEO Staff/Planners

Nichole Lainhart–no disclosures to report.

Chelsey Goins, PhD–no disclosures to report.

Scott J. Hershman, MD, FACEHP, CHCP–no disclosures to report.

Sandra Caballero, PharmD–no disclosures to report.

Sharon Tordoff–no disclosures to report.

All identified conflicts of interest have been mitigated.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the U.S. Food and Drug Administration (FDA). The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

© 2025 CME OUTFITTERS. ALL RIGHTS RESERVED.

THE FORCE AWAKENS

Unlocking the Potential of IL-23–Targeted Therapies in the Treatment of IBD

Instructions for Interactive Technology

Use one of the iPads provided at your table to answer polling questions, view onsite presentations, and submit questions to the faculty.

Ask Faculty a Question

Select the Ask Question tab below the slide viewer to submit a question. If your question is for a specific faculty member, please include their name. Your question will be shared with the faculty for the question-and-answer portion of the session.

View and Take Notes on Presentation Slides

Select the Take Notes tab to take notes during the meeting. All of the notes you take during the meeting will be emailed to the address provided within 5 business days.

Obtaining Credit

To receive CME/CE credit for this activity, scan the QR code to login to or create a learner account.

Downloadable Resources

Downloadable resources will be available at **cmeoutfitters.com/unlockresources**.

Engage with Us

Follow us **@cmeoutfitters** for announcements about upcoming CME opportunities, health care news, and more!

Thank you for joining us today!

CME OUTFITTERS

© 2025 CME OUTFITTERS. ALL RIGHTS RESERVED.

CLOSING GAPS IN CARE FOR

Short Bowel Syndrome in the Community Setting



BOOK A LIVE OR VIRTUAL
Grand Rounds Today!

CME OUTFITTERS

Contact **Moriah Aponte**
apontem@cmeoutfitters.com